Allergan’s most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $170.00 short call and a strike $180.00 long call offers a potential 22.55% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $170.00 by expiration. The full premium credit of $1.84 would be kept by the premium seller. The risk of $8.16 would be incurred if the stock rose above the $180.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 26.67 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Jim Cramer: Drug Stocks on the Move
Sat, 17 Feb 2018 00:01:00 +0000
We could be poised for even a further advance PROVIDED that we stay oversold.
Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
Fri, 16 Feb 2018 23:58:00 +0000
DUBLIN , Feb. 16, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego , February …
Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2017
Fri, 16 Feb 2018 22:48:05 +0000
Allergan PLC (NYSE:AGN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
United Therapeutics reaches patent settlement with Actavis
Fri, 16 Feb 2018 20:31:53 +0000
Silver Spring biotech United Therapeutics Corp.’s share price was largely unchanged Friday after announcing it settled litigation with Actavis Laboratories FL Inc. in a deal that will allow that company to market a generic version of one of United Therapeutics’ hypertension drugs. Under the settlement, United Therapeutics (UTHR) grants the Teva Pharmaceutical Industries Ltd. (TEVA) subsidiary a license to manufacture and commercialize a generic version of Orenitram — an extended-release, oral tablet form of treprostinil —beginning June 15, 2027. Actavis had filed a challenge seeking to market the generic Orenitram before United Therapeutics’ patents expire between 2024 and 2031.
United Therapeutics settles patent litigation over $157M drug
Fri, 16 Feb 2018 20:16:21 +0000
United Therapeutics has settled patent litigation over a $157 million drug. The company (UTHR) reached an agreement with Actavis Laboratories FL, which is a subsidiary of generic giant Teva Pharmaceuticals, that resolves litigation over certain patents related to one of United Therapeutics’ pulmonary arterial hypertension drugs: Orenitram. The settlement agreement allows Actavis to begin manufacturing and commercializing a generic version of the drug in June 2027 or potentially earlier under some circumstances. However, United Therapeutics noted that the agreement doesn’t allow Actavis to manufacture generic versions of other products like Tyvaso or Remodulin.
Also on Market Tamer…
Follow Us on Facebook